We’re currently obsessed with the downstream debris of aging. We pour billions into clearing senescent cells or patching up mitochondrial decay, yet we treat the cell’s internal control language—post-translational modifications (PTMs)—as mere background noise. These modifications dictate how the cell responds to stress in real time, but they’re consistently overlooked.

Take SUMOylation. It’s a key rheostat for chromatin stability and protein homeostasis. When the SUMO-conjugation machinery falters, the nucleus becomes a disorganized mess, accelerating the very transcriptomic drift we call aging. Still, while we fund another round of senolytics that might buy a few months of tissue health, we’re starving foundational research into proteostatic signaling.

We’re building a house of cards and wondering why it collapses, all while ignoring the glue holding the structure together.

Funding agencies prioritize what’s "druggable"—receptors and enzymes that fit neatly into high-throughput screens. But aging isn't a single target; it's a system-wide failure of regulatory fidelity. If we don’t understand how the cell manages its SUMO-1/2/3 dynamics in a senescent environment, we aren't reversing aging—we’re just shuffling deck chairs on the Titanic.

It’s time to pivot. We need a massive injection of capital into systems-level biochemistry, specifically aimed at the regulators of the epigenome. We need to map the "proteostatic clock" before we try to turn back its hands.

I’m looking for collaborators—biochemists, computational biologists, and bold thinkers—who are tired of chasing peripheral pathways. We need to build a comprehensive atlas of how these regulatory modifications shift over a human lifespan. If we don’t prioritize the language of the cell, we’ll never gain the authority to rewrite its destiny.

Who’s ready to stop patching the walls and start fixing the foundation?